Back to today’s briefing

Story perspectives

Breakthrough Drug Tavapadon Shows Promise for Parkinson's Treatment

4/11/2025

26 2

Summary

Story summary

Tavapadon, a promising oral treatment for early-stage Parkinson's disease, demonstrated remarkable safety and effectiveness in two Phase 3 trials, TEMPO-1 and TEMPO-2. Patients reported enhanced motor function within just a month, experiencing fewer side effects compared to conventional therapies. AbbVie is poised to pursue regulatory approval following these compelling results shared at the AAN annual meeting.

1 of 1

Story summary

Tavapadon, a promising oral treatment for early-stage Parkinson's disease, demonstrated remarkable safety and effectiveness in two Phase 3 trials, TEMPO-1 and TEMPO-2. Patients reported enhanced motor function within just a month, experiencing fewer side effects compared to conventional therapies. AbbVie is poised to pursue regulatory approval following these compelling results shared at the AAN annual meeting.